744497
Last Update Posted: 2016-10-17
Recruiting has ended
Males accepted | 18 Years + |
1930 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
The purpose of this study is to determine whether survival can be prolonged in patients with castration-resistant prostate cancer who receive dasatinib with docetaxel and prednisone.
Eligibility
Relevant conditions:
Prostatic Neoplasms
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov